• Search History (Register)
  • MeSH Browser
Sort by Relevance
Search Results [216 Hits] Selected Records [0 Hits] [Clear]
Year Source Title
2019 The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Ixazomib]
2019 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daratumumab (multiple myeloma) - Addendum to Commission A18-66]
2019 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pomalidomide (multiple myeloma) - Benefit assessment according to §35a Social Code Book V]
2019 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pomalidomide (multiple myeloma) - Addendum to Commission A19-50]
2019 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elotuzumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V]
2019 National Institute for Health and Care Excellence (NICE) Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib. NICE technology appraisal guidance 586
2019 National Institute for Health and Care Excellence (NICE) Lenalidomide plus dexamethasone for previously untreated multiple myeloma. NICE technology appraisal guidance 587
2019 National Institute for Health and Care Excellence (NICE) Pomalidomide with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal). NICE technology appraisal guidance 602
2019 National Institute for Health and Care Excellence (NICE) Lenalidomide with bortezomib and dexamethasone for untreated multiple myeloma (terminated appraisal). NICE technology appraisal guidance 603
2018 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Daratumumab (Darzalex®) in combination with bortezomib, melphalan and prednisone for untreated myeloma
2018 Institute for Clinical Effectiveness and Health Policy (IECS) [Pomalidomide combined with dexamethasone in multiple myeloma]
2018 Institute for Clinical Effectiveness and Health Policy (IECS) [Daratumumab for relapsed or refractory multiple myeloma]
2018 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Carfilzomib (multiple myeloma) - Addendum to Commission A17-38]
2018 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daratumumab (multiple myeloma) - Addendum to Commission A17-40]
2018 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daratumumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V]
2018 National Institute for Health and Care Excellence (NICE) Denosumab for preventing skeletal-related events in multiple myeloma (terminated appraisal). NICE technology appraisal guidance 549
2017 HAYES, Inc. clonoSEQ (Adaptive Biotechnologies)
2017 Institute for Clinical Effectiveness and Health Policy (IECS) [Pomalidomide for relapsed and refractory myeloma]
2017 Technology Assessment Unit of the McGill University Health Centre (MUHC) Plerixafor as first-line choice for stem cell mobilization in non-Hodgkin's lymphoma and multiple myeloma patients
2017 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ixazomib (multiple myeloma) - Assessment according to § 35a (para. 1, sentence 10) Social Code Book V]
2017 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Carfilzomib (multiple myeloma) - Benefit assessment according to §35a Social Code Book V]
2017 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daratumumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V]
2017 National Institute for Health and Care Excellence (NICE) Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib. NICE technology appraisal guidance 427
2017 National Institute for Health and Care Excellence (NICE) Elotuzumab for previously treated multiple myeloma (terminated appraisal). NICE technology appraisal guidance 434
2017 National Institute for Health and Care Excellence (NICE) Bortezomib for treating multiple myeloma after second or subsequent relapse (terminated appraisal). NICE technology appraisal guidance 453
2017 National Institute for Health and Care Excellence (NICE) Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal). NICE technology appraisal guidance 454
2016 NIHR Horizon Scanning Centre (NIHR HSC) Daratumumab with bortezomib and dexamethasone for relapsed or refractory multiple myeloma – second line
2016 NIHR Horizon Scanning Centre (NIHR HSC) Reolysin for relapsed or refractory multiple myeloma
2016 NIHR Horizon Scanning Centre (NIHR HSC) Carfilzomib (Kyprolis) in combination with dexamethasone for relapsed multiple myeloma – second line
2016 Health Quality Ontario (HQO) Vertebral augmentation involving vertebroplasty or kyphoplasty for cancer-related vertebral compression fractures: OHTAC recommendation
2016 NIHR Horizon Scanning Centre (NIHR HSC) Carfilzomib (Kyprolis) in combination with melphalan and prednisone for multiple myeloma – first line
2016 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Ixazomib (Ninlaro®) in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma (MM)
2016 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pomalidomide - Addendum to Commission A15-42]
2016 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Carfilzomib - Assessment according to §35a (para. 1., sentence 10) Social Code Book V]
2016 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elotuzumab - Benefit assessment according to §35a Social Code Book V]
2016 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daratumumab - Assessment according to §35a (para. 1., sentence 10) Social Code Book V]
2016 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Carfilzomib (multiple myeloma; combination with dexamethasone alone) - Assessment according to § 35a (para. 1, sentence 10) Social Code Book V]
2016 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elotuzumab (multiple myeloma) - Addendum to Commission A16-32]
2016 National Institute for Health and Care Excellence (NICE) Panobinostat for treating multiple myeloma after at least 2 previous treatments. NICE technology appraisal guidance 380
2015 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Pomalidomide (Imnovid®)
2015 Canadian Agency for Drugs and Technologies in Health (CADTH) Protein testing in patients with multiple myeloma: a review of clinical effectiveness and guidelines
2015 NIHR Horizon Scanning Centre (NIHR HSC) Elotuzumab with lenalidomide for multiple myeloma – first line
2015 NIHR Horizon Scanning Centre (NIHR HSC) Daratumumab monotherapy for relapsed and refractory multiple myeloma
2015 NIHR Horizon Scanning Centre (NIHR HSC) Daratumumab with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma
2015 NIHR Horizon Scanning Centre (NIHR HSC) Plitidepsin (Aplidin) for relapsed and refractory multiple myeloma – fourth line
2015 NIHR Horizon Scanning Centre (NIHR HSC) Seralite® for multiple myeloma and other B cell dyscrasias
2015 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Carfilzomib (Kyprolis®) for patients with relapsed multiple myeloma who have received one to three prior lines of therapy
2015 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Stem cell transplantation for multiple myeloma (follow-up commission to Commission N05-03C)]
2015 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Panobinostat: assessment according to §35a (para. 1., sentence 10) Social Code Book V]
2015 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pomalidomide: benefit assessment according to §35a Social Code Book V]
2014 NIHR Horizon Scanning Centre (NIHR HSC) Ixazomib citrate for relapsed and/or refractory multiple myeloma
2014 HAYES, Inc. Myeloma prognostic risk signature (MyPRS) test for myeloma
2014 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Bortezomib (Velcade®)
2014 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Theralite for treatment of renal failure in patients with multiple myeloma
2014 National Institute for Health and Care Excellence (NICE) Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation. NICE technology appraisal guidance 311
2013 NIHR Horizon Scanning Centre (NIHR HSC) Plitidepsin (Aplidin) in combination with dexamethasone for multiple myeloma – third line
2013 NIHR Horizon Scanning Centre (NIHR HSC) Elotuzumab for relapsed or refractory multiple myeloma
2013 NIHR Horizon Scanning Centre (NIHR HSC) Carfilzomib for relapsed and/or refractory multiple myeloma
2013 NIHR Health Technology Assessment programme Bortezomib for induction therapy in multiple myeloma before high dose chemotherapy and autologous stem cell transplantation
2013 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Pomalidomide (Pomalyst®) for the treatment of refractory multiple myeloma or relapsed and refractory multiple myeloma
2013 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pomalidomide - Assessment according to § 35a (para. 1, sentence 10) Social Code Book V (dossier assessment))]
2012 NIHR Horizon Scanning Centre (NIHR HSC) Panobinostat (Faridak) for relapsed or refractory multiple myeloma
2012 HAYES, Inc. Percutaneous kyphoplasty
2012 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Bortezomib (Velcade®) as consolidation or maintenance therapy after autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma
2012 NIHR Horizon Scanning Centre (NIHR HSC) Carfilzomib (Kryprolis) for multiple myeloma – third line
2012 NIHR Horizon Scanning Centre (NIHR HSC) Bortezomib (Velcade) in combination with dexamethasone or pegylated liposomal doxorubicin for relapsed multiple myeloma
2012 NIHR Horizon Scanning Centre (NIHR HSC) Pomalidomide for multiple myeloma – third line
2012 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Lenalidomide (Revlimid®) for the first-line therapy of transplant-ineligible patients with multiple myeloma
2012 HAYES, Inc. In utero fetal surgery for myelomeningocele
2012 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Bortezomib (Velcade®) 3.5 mg subcutaneous injection
2011 NIHR Health Technology Assessment programme The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation
2011 NIHR Health Technology Assessment programme The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation
2011 Institute for Clinical Effectiveness and Health Policy (IECS) [Percutaneous acrylic vertebroplasty for the treatment of vertebral fractures]
2011 NIHR Horizon Scanning Centre (NIHR HSC) Bortezomib (Velcade) for multiple myeloma within a transplant setting
2011 The Regional Health Technology Assessment Centre (HTA-centrum) [Treatment in relapsed multiple myeloma; bortezomib, lenalidomide, thalidomide]
2011 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Stem cell transplantation for multiple myeloma]
2011 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Stem cell transplantation for multiple myeloma: assessment of the BMT CTN 0102 study]
2011 National Institute for Health and Care Excellence (NICE) Bortezomib and thalidomide for the first-line treatment of multiple myeloma. NICE technology appraisal guidance 228
2011 National Institute for Health and Care Excellence (NICE) Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia. NICE technology appraisal guidance 218
2010 Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Plerixafor (Mozobil) in patients with lymphoma and multiple myeloma]
2010 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Plerixafor (Mozobil) for autologous stem cell transplantation in patients with lymphoma and multiple myeloma
2010 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Bendamustine (Ribomustin/Treanda/ Levact) for indolent non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukaemia (CLL) and multiple myeloma
2010 NIHR Horizon Scanning Centre (NIHR HSC) Vorinostat for refractory multiple myeloma
2010 NIHR Horizon Scanning Centre (NIHR HSC) Lenalidomide (Revlimid) for newly diagnosed multiple myeloma
2010 Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Percutaneous vertebroplasty as a treatment for osteoporotic vertebral fractures - a health technology assessment]
2010 HAYES, Inc. Autologous stem cell transplantation followed by nonmyeloablative allogeneic stem cell transplantation for treatment of multiple myeloma
2010 HAYES, Inc. Brainstem Auditory Evoked Response (BAER) for assessment of brainstem dysfunction in patients with chiari malformations
2010 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Plerixafor (Mozobil®)
2010 NIHR Health Technology Assessment programme Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia
2009 Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of Bortezomib in treating refractory multiple myeloma]
2009 NIHR Health Technology Assessment programme Bortezomib for the treatment of multiple myeloma patients
2009 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Thalidomide (Thalidomide Pharmion®) in combination with melphalan and prednisone as first line treatment of patients with untreated multiple myeloma, aged GE 65 years or ineligible for high dose chemotherapy
2008 Institute for Clinical Effectiveness and Health Policy (IECS) Effectiveness of lenalidomide in multiple myeloma patients
2008 NIHR Horizon Scanning Centre (NIHR HSC) Denosumab (AMG 162) for bone metastases from solid tumours and multiple myeloma
2008 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Lenalidomide (Revlimid®) for multiple myeloma
2007 Institute for Clinical Effectiveness and Health Policy (IECS) Effectiveness of third ventricle neuroendoscopy in hydrocephalus
2007 The Swedish Council on Health Technology Assessment (SBU) Percutaneous vertebroplasty in severe back pain from vertebral compression fractures - early assessment briefs (Alert)
2007 Quality Improvement Scotland (NHS QIS ) Bortezomib monotherapy for relapsed multiple myeloma
2007 NIHR Horizon Scanning Centre (NIHR HSC) Bortezomib (Velcade) for first-line multiple myeloma
2007 NIHR Horizon Scanning Centre (NIHR HSC) Plerixafor (Mozobil) for stem-cell mobilisation in multiple myeloma